|
Workshop
[In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
Speakers:
Chandra Prakash, Agios; Zhixia Yan, FDA; Bernard Murray, Gilead; Ryan Takahashi, Denali Therapeutics; Shuai Wang, Genentech; Raman Sharma, Pfizer; Ronald Kong, PTC Therapeutics, Inc.
Organizers:
Chandra Prakash (Agios)
Date:
2024-05-06
Time:
8:45-17:00 Pacific Time
Registration fee:
Regular attendees: $295; Academic/Students/Postdocs: $45; Out-of-Pocket: $45; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $975; Lunch Sponsorship: $1250; On-site Registration: $500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(11)Celerion; Certara; Cyprotex; Discovery Life Sciences; Ellegaard BioResearch; Eurofins Selcia; Labcorp; MilliporeSigma [Sigma-Aldrich,Inc.]; Moravek, Inc.; Q Squared Solutions; Quotient Sciences
Registration: http://www.PBSS.org
Registration deadline:2024-05-02
(it will close sooner if the seating cap is reached)
About the Topic
Human absorption, distribution, metabolism, and excretion (ADME) study (also referred to as mass balance or radiolabel study) is a key study in the Clinical Pharmacology package of new drug application. The data gathered from this study provides a quantitative and comprehensive overall picture of the disposition of a drug, including excretion pattern and metabolite profiles in circulation and excreta and are highly informative for developing a cohesive strategy for clinical pharmacology studies, drug-drug interaction, organ impairment, monitoring of metabolite(s), and to obtain a waiver for the bioequivalence study. Regulatory guidelines (Metabolites in Safety Testing, MIST) warrant that human specific or disproportionate metabolites whose exposure is greater than 10% of total drug related material should be considered for safety assessment in preclinical species. Recently, US Food and Drug Administration (FDA) issued a guidance describing the recommendations regarding clinical pharmacology considerations for conducting human radiolabeled mass balance studies of investigational drug.
The workshop is designed to provide detailed guidance on objectives, study designs, and data analysis of metabolism studies of small molecules. Speakers of this workshop bring a wealth of knowledge from the pharmaceutical industry/FDA in drug metabolism sciences. This workshop will describe the highlights of this regulatory guidance and various strategies and technical approaches for conducting the human radiolabeled ADME studies with examples of approved drugs.
The discussion will be centered around the following topics:
- Overview of the recent FDA guidance
- Radiolabeled human ADME studies-why, what and when
- Human ADME studies: Design, data analysis, and interpretation
- Approaches for safety assessments of human metabolites
- IV tracer studies approach with case studies
Time (PST) |
Topic |
Presenter |
8:45-8:55 am |
PBSS Welcome and Introduction |
Shichang Miao, PhD, PBSS |
8:55-9:20 am |
Objectives and Overview of Various Approaches Used for hADME Studies: Pros and Cons |
Chandra Prakash, Senior Research Fellow, Agios Pharmaceuticals |
9:20-9:50 am |
Importance of Preclinical Radiolabeled ADME Studies |
Chandra Prakash, Senior Research Fellow, Agios Pharmaceuticals |
9:50 -10:30 am |
Nonclinical QWBA Studies and their Application in Human Dosimetry Calculations |
Bernard Murray, PhD, Executive Director, Drug Metabolism, Gilead Sciences |
10:30-10:40 am |
Major Sponsor Presentation |
Fortrea |
10:40-11:00 am |
Break and Vendor Show |
- |
11:00-11:50 am |
A Deep Dive: FDA Draft Guidance on Human Radiolabeled Mass Balance Studies |
Zhixia (Grace) Yan Danielsen, PhD, Deputy Division Director, US Food and Drug Administration |
11:50 am-12:50 pm |
Lunch |
Sponsor, TBD |
12:50-1:40 pm |
Human Mass Balance and Metabolite Profiling: Design, Data Analysis, and Interpretation |
Shuai Wang, PhD, Principal Scientist, DMPK, Genentech |
1:40-2:30 pm |
hADME Studies at Steady State: Design and Case Studies |
Ronald Kong, PhD, Vice President, Clinical Pharmacology and DMPK, PTC Therapeutics. |
2:30-2:40 pm |
Major Sponsor Presentation |
Pharmaron |
2:40-3:00 pm |
Break and Vendor Show |
- |
3:00-3:50 pm |
Approaches for the Determination of Absolute Bioavailability: Study Design, Data Analysis, and Interpretation |
Raman Sharma, Senior Scientist, Pfizer |
3:50-4:30 pm |
Approaches for Coverage Assessment of Human Metabolites in Safety Species (MIST) |
Ryan Takahashi, PhD, Head of Small Molecule DMPK, Denali Therapeutics |
4:30-5:00 pm |
Panel Discussion |
All speakers |
5:00-6:00 pm |
Happy Hour |
Sponsor, Labcorp |
2024-08-14, [Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)
|
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
|
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
|
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapeutics
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Simulations Plus
GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|